Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older. An implanted ...

The wearable device is called Optune. You get it with chemotherapy after surgery and radiation. The FDA has approved it for both newly diagnosed people and people whose glioblastoma has come back.

The results are the most significant increases in both survival rates reported in a phase 3 trial for newly diagnosed GBM. Median overall survival was also improved in the Optune plus ...

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM).

The result is constraints in what is available to GBM patients. For instance, the guidelines state: “Do not offer Tumor Treating Fields”, which means that you cannot get Optune on the NHS ...

We remain committed to exploring opportunities to further extend the survival horizon for patients diagnosed with glioblastoma.” Optune Gio® is currently approved for ...

The treatments can be used together to extend the survival of glioblastoma patients. But the Optune device, which has a list price of $27,000 a month, is rarely used in Canada because the ...

The median life expectancy for someone with glioblastoma is about 14 months ... and I'm also wearing a device on my head called an Optune. It's a series of ceramic arrays that are kind of glued ...

Novocure’s FDA-approved TTF therapy device, Optune, has shown modest results in extending life spans for glioblastoma patients. Patients in Novocure’s phase 3 trial who wore the device 70-80% ...

In October, the FDA approved Novocure’s new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma (GBM). In December ...

Novocure's FDA-approved TTF therapy device, Optune, has shown modest results in extending life spans for glioblastoma patients. Patients in Novocure's Phase III trial who wore the device 70–80% ...